Christopher J. Coughlin

Christopher J. Coughlin has sat on the boards of five US companies, and the record leans almost entirely toward buying: 19 purchases worth EUR 5.7 million (median EUR 84,820), against a single sale, EUR 62,307 on May 14, 2024. Purchases make up 95% of the open-market trades.

The three largest are dated December 5, 2017 (EUR 1,375,998), April 30, 2018 (EUR 999,815) and April 29, 2022 (EUR 929,571). Fifteen purchases are filed at Allergan plc, two at Centene Corp and two at Alexion Pharmaceuticals Inc. Dun & Bradstreet (7 filings) and Prestige Consumer Healthcare Inc. (4) have no open-market trade.

In all, 84 filings were published between March 15, 2016 and September 30, 2026, with 56 share grants and 2 option exercises. The year 2018 is the busiest, with 18 filings. Five filings fall in the last twelve months, with neither a purchase nor a sale.

Coughlin has 14, 14 and 2 own market trades within 30 days of colleagues, in that order. All in the same direction. Colleagues in order: Joseph H. Boccuzi (Allergan plc), Thomas C. Freyman (Allergan plc) and H. James Dallas (Centene Corp).